PET imaging of the brain demonstrates that a slow-release formula of a drug used to treat attention-deficit/hyperactivity disorder is as effective as a rapid-release version and less likely to be abused.
PET imaging of the brain demonstrates that a slow-release formula of a drug used to treat attention-deficit/hyperactivity disorder is as effective as a rapid-release version and less likely to be abused.
Dr. Thomas J. Spencer, assistant director of the pediatric psychopharmacology unit at Massachusetts General Hospital, and colleagues used carbon-11 altropane PET to investigate a new once-a-day capsule developed to slowly release methylphenidate.
The drug boosts dopamine activity in the frontal cortex and improves the ability to pay attention. But it may also lead to patient abuse.
The researchers evaluated 12 healthy adults randomly assigned to receive immediate-release or osmotic-release methylphenidate. PET showed that the 90-mg osmotic-release capsule produced the same effects as 40 mg of immediate-release methylphenidate. They reported their results in the March American Journal of Psychiatry.
BrightHeart Garners Third FDA Clearance for AI-Powered Assessments of Fetal Heart Ultrasound
May 14th 2025The latest FDA 510(k) clearance is for B-Right Views, an AI-enabled device, which provides automated detection of required views necessary for second- and third-trimester fetal heart ultrasound exams.